ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced a retrospective data analysis from the CHAMPION clinical trial showing significant a reduction in 30-day hospital readmission rates for patients age 65 and older. The CHAMPION trial looked at the safety and effectiveness of the CardioMEMS™ HF System for patients with New York Heart Association (NYHA) Class III heart failure (HF) who had been hospitalized for HF in the previous 12 months. The analysis — Impact of Wireless Pulmonary Artery Pressure Monitoring on Heart Failure Hospitalization and All-Cause 30-Day Readmissions in Medicare-Eligible patients with NYHA Class III Heart Failure — was presented during the American Heart Association Scientific Sessions.
This analysis looked at patients 65 and older (Medicare-eligible) from the CHAMPION trial and found that there was a 58 percent reduction in all-cause hospital readmissions (hospitalization for any reason) and a 78 percent reduction in HF hospital readmissions when patients were managed with the CardioMEMS HF System compared to standard-of-care medical management. These findings suggest that use of the CardioMEMS HF System can significantly reduce the hospital’s risk of government-imposed penalties that are designed to reduce patient readmissions within 30 days of treatment.
The CardioMEMS system uses a miniaturized, wireless monitoring sensor that is implanted in the pulmonary artery (PA) during a minimally invasive procedure to directly measure PA pressure. Measuring PA pressure allows clinicians to proactively manage treatment with medication changes for patients with worsening HF before visible symptoms, such as weight and blood pressure changes, occur. The system allows patients to transmit PA pressure data from their homes to their health care providers, who then manage appropriate medication changes to reduce the likelihood of hospitalization.
Under the U.S. Centers for Medicare and Medicaid Services (CMS) Hospital Readmissions Reduction Program (HRRP), hospitals with excess all-cause 30-day readmissions (a hospital specific CMS adjustment compared with the national average) for HF, heart attack and pneumonia discharges were penalized $227 million for fiscal year 2014. The penalty fees list in 2015 will also include chronic obstructive pulmonary disease (COPD), total hip and total knee replacement and the estimated penalties are projected at $428 million. The hospital penalties extend across total Medicare payments based on the performance of these specific conditions.
“Incorporating proactive pulmonary artery pressure monitoring into patient management significantly reduced heart failure hospitalizations and 30-day all-cause and HF readmissions in patients age 65 and older. The adoption of this treatment strategy using the CardioMEMS HF System addresses the unmet need within the U.S. health care system for hospitals struggling to meet the requirements of CMS,” said Dr. Philip Adamson, MC Director of the Heart Failure Institute at Oklahoma Heart Hospital in Oklahoma City.
“These data are recognition of the importance the CardioMEMS HF System brings to heart failure patients burdened with multiple hospital admissions each year and the cost-savings it brings to the health care system,” said Dr. Mark D. Carlson, chief medical officer for St. Jude Medical. “We continue our commitment of investing in meaningful clinical research with this new data analysis from the CHAMPION trial that is helping shape the way physicians are caring for their patients.”
Heart failure occurs when the heart is unable to pump enough blood to meet the body’s demands and blood pressure within the heart is elevated. Significant HF progression over a period of days is known as acute decompensation and leads to hospitalization. Increased PA pressures often precede indirect measures of worsening HF such as weight and blood pressure changes. The CardioMEMS HF System, approved by the U.S. Food and Drug Administration in May 2014, allows clinicians to stabilize PA pressures by proactively managing medications and other treatment options while also providing an early indication of worsening HF.
Click here to learn more about the CardioMEMS™ HF System.
About St. Jude Medical’s Heart Failure Business
Approximately
26
million people worldwide suffer from heart failure. St. Jude Medical
collaborates with heart failure specialists, clinicians and advocacy
partners to provide innovative, cost-effective solutions for heart
failure patients around the world. For more information about St. Jude
Medical’s focus on heart failure, visit the St.
Jude Medical Heart Failure Media Kit.
About St. Jude Medical
St. Jude Medical is a global medical
device manufacturer dedicated to transforming the treatment of some of
the world’s most expensive epidemic diseases. The company does this by
developing cost-effective medical technologies that save and improve
lives of patients around the world. Headquartered in St. Paul, Minn.,
St. Jude Medical has four major clinical focus areas that include
cardiac rhythm management, atrial fibrillation, cardiovascular and
neuromodulation. For more information, please visit sjm.com
or follow us on Twitter @SJM_Media.
Forward-Looking Statements
This news release contains
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995 that involve risks and uncertainties. Such
forward-looking statements include the expectations, plans and prospects
for the Company, including potential clinical successes, anticipated
regulatory approvals and future product launches, and projected
revenues, margins, earnings and market shares. The statements made by
the Company are based upon management’s current expectations and are
subject to certain risks and uncertainties that could cause actual
results to differ materially from those described in the forward-looking
statements. These risks and uncertainties include market conditions and
other factors beyond the Company’s control and the risk factors and
other cautionary statements described in the Company’s filings with the
SEC, including those described in the Risk Factors and Cautionary
Statements sections of the Company’s Annual Report on Form 10-K for the
fiscal year ended December 28, 2013 and Quarterly Report on Form 10-Q
for the fiscal quarter ended September 27, 2014. The Company does not
intend to update these statements and undertakes no duty to any person
to provide any such update under any circumstance.
